Modern haemophilia care.
Erik Berntorp, Amy D Shapiro
https://pubmed.ncbi.nlm.nih.gov/22456059/Actively Recruiting
Led by Pfizer · Updated on 2026-10-07
173
Participants Needed
39
Research Sites
N/A
Total Duration
This research aims to understand the long-term safety and effectiveness of two gene therapies, giroctocogene fitelparvovec and fidanacogene elaparvovec, in patients with Hemophilia A or Hemophilia B who have previously received these treatments through Pfizer-sponsored clinical trials. The study collects data based on standard medical care without administering any new investigational products. Participants in this study have already been treated with one of the two gene therapies in prior studies and will not receive additional experimental treatments in this trial. Instead, the study involves ongoing observation and data collection related to their health status, including diagnostic testing for liver-related conditions when clinically indicated. During the study, participants will attend visits aligned with their routine care where researchers will assess outcomes such as the incidence of blood clots, development of inhibitors, liver abnormalities, and factor activity levels over a period of up to 10 years. Additional measures include bleeding rates, factor consumption, autoimmune disorders, and quality of life assessments, ensuring comprehensive long-term monitoring of safety and effectiveness.
CONDITIONS
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
P
Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Post‑AAV Gene Therapy Follow‑Up | Standard Prophylactic Factor Replacement |
|---|---|---|
| What it is | Long‑term safety and vector integration monitoring after previous AAV gene therapy in Hemophilia A or B participants | Regular factor VIII or IX prophylaxis infusions to prevent bleeding events |
| Role in trial | Single‑group observational follow‑up safety study | Standard comparator treatment not part of this trial protocol |
| Primary use | Monitoring for adverse events such as thromboembolic events, malignancy, inhibitors, liver abnormalities over 10 years | Routine prevention of bleeding by replacing missing clotting factor |
| How it is performed | Safety assessments including clinical monitoring and laboratory evaluation over up to 10 years | Periodic intravenous factor infusions as routine prophylaxis |
| Evidence status | Evidence limited to ongoing follow‑up of AAV‑treated individuals; no efficacy conclusions yet | Well‑established to reduce bleeding rates in hemophilia A and B |
| Important risks | Long‑term risks under investigation include thromboembolic events, malignancy, inhibitor development, liver abnormalities | Risk of infusion‑related reactions or inhibitor development, generally well managed |
| Important limitations | No control group; limited generalizability; long‑term safety data still emerging | Requires frequent intravenous administration and does not address underlying genetic deficiency |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants attend visits aligned with their routine care to collect data and monitor safety and effectiveness of previous gene therapy treatment over up to 10 years.
Visits based on standard of care
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Erik Berntorp, Amy D Shapiro
https://pubmed.ncbi.nlm.nih.gov/22456059/V S Blanchette, M McCready, C Achonu...
https://pubmed.ncbi.nlm.nih.gov/12709033/David Lillicrap
https://pubmed.ncbi.nlm.nih.gov/18929522/V S Blanchette, N S Key, L R Ljung...
https://pubmed.ncbi.nlm.nih.gov/25059285/Pfizer
Lead Sponsor